Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Understand the role of reproductive biotech in overcoming biological limits in fertility treatments and enhancing success ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...